20 Apr 2011 16:05
20 April 2011
Plethora Solutions Holdings plc
("Plethora" or the "Company")
Result of General Meeting
Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces that all resolutions were duly passed at the General Meeting of the Company held earlier today.
The remaining conditions in relation to the placing have been satisfied. The placing (the "Placing") of 11,400,000 new ordinary shares of 1 penny each, at a price of 7.5 pence per share (the "Placing Shares") is unconditional save for admission of the Placing Shares to AIM ("Admission").
The Placing Shares will, on Admission, be credited as fully paid and will have the same rights in all respects with the existing ordinary shares, including the right to receive all dividends and other distributions declared.
It is expected that Admission will be effective and trading will commence at 8:00 am on 21 April 2010. Following Admission, the Company will have 65,725,800 Ordinary Shares in issue. Since the Company holds no shares in Treasury, the total number of voting rights in the Company is therefore 65,725,800 and this figure may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.
Enquiries:
Plethora Solutions Bill Robinson, Chairman Ronald Openshaw, CEO | Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) Antony Legge (Nomad) Martin Lampshire (Broker) | Tel : +44(0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce | Tel: +44(0) 20 7947 4350
|
Hansard Communications Nicholas Nelson/Guy McDougall | Tel: +44(0) 20 7245 1100
|
About Plethora: www.plethorasolutions.co.uk.
Plethora is a speciality pharmaceutical company focused on the treatment of urology, gynaecology, andrology, obstetric conditions and sexual health. The Company initially developed products for the treatment of premature ejaculation (PSD502), interstitial cystitis (PSD597), erectile dysfunction (PSD510), stress urinary incontinence (PSD503), and overactive bladder (PSD506). Plethora's subsidiary, The Urology Company Limited, established in 2009, markets and distributes a range of therapeutic products. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L).